MONOVISC®

What Is Monovisc® Injection?

Monovisc® is an advanced hyaluronic acid orthopaedic injection designed to alleviate pain associated with osteoarthritis.

Unlike other viscosupplements, it requires only a single administration, making it a convenient option for patients and practitioners alike. This injection works by restoring the natural viscosity and elasticity of the synovial fluid, thereby reducing pain and improving mobility.

The importance of Monovisc® in clinical practice lies in its ability to offer long-lasting relief with minimal intervention. It is especially beneficial for patients who have not responded to conservative treatments like physical therapy or oral medications.

Nu Derma Supply catalogue offers specialised professionals the opportunity to shop for Monovisc® Injections at wholesale pricing, with special discounts and fast delivery.

What Is It Used for?

Monovisc® injections are particularly effective for patients who have not responded adequately to pain medication or physical therapy:

• Relieving pain: Provides significant relief in patients with osteoarthritis of the knee.
• Improving joint mobility: Enhances the range of motion and flexibility.
• Delaying surgical intervention: Offers a non-surgical option for managing osteoarthritis, potentially delaying the need for knee replacement surgery.
• Enhancing lubrication: Mimics natural synovial fluid to provide better lubrication and shock absorption.
• Reducing inflammation: Helps to alleviate inflammation associated with osteoarthritis.

Who Is the Manufacturer?

Monovisc® is manufactured by Anika Therapeutics, Inc., a global medical technology company based in Bedford, Massachusetts, USA.

Founded in 1992, Anika Therapeutics specialises in developing and producing high-quality, minimally invasive therapies for joint health and pain management.

Benefits and Results of Use

Treatment with Monovisc® injections offers numerous benefits and can significantly improve the quality of life for those suffering from osteoarthritis, including:

• Single-dose convenience: Requires only one session, making it more convenient compared to other multi-dose HA treatments.
• Long-lasting pain relief: Provides up to half a year of relief from osteoarthritis symptoms.
• Improved joint function: Helps restore natural movement and flexibility.
• Minimal side effects: Fewer complications compared to surgical options.
• Non-surgical option: Ideal for patients looking to delay or avoid knee replacement surgery.
• Reduced need for pain medication: Decreases reliance on oral painkillers, which can have adverse effects with long-term use.
• Enhanced patient compliance: One-time treatment reduces the burden of multiple doctor visits.
• Minimal recovery time: Allows patients to resume normal activities relatively quickly.

Main Ingredients and Device Properties

Monovisc® is composed of carefully formulated ingredients to elevate osteoarthritis discomfort.

Main ingredients:

• Cross-linked sodium hyaluronate: 22 mg/ml.
• Potassium chloride: 0.8 mg.
• Sodium chloride: 36 mg.
• Potassium phosphate, monobasic: 0.8 mg USP.
• Sodium phosphate, dibasic: 4.6 mg.
• Water for injection: q.s. to 4 ml.

 

Device properties:

• Single-use: Pre-filled syringe for one-time use.
• Sterile: Manufactured under sterile conditions to prevent contamination.
• Non-animal derived: Reduces the risk of an allergic reaction.

Does It Work the Same as Hyaluronic Acid(HA)?

Yes, Monovisc® is a type of HA treatment.

However, it is a specially formulated, cross-linked version designed to provide longer-lasting effects compared to regular HA.

Accessories or Items Included

Monovisc® is delivered with all necessary accessories for immediate administration:

• 1 pre-filled syringe: 4 ml syringe containing 88 mg of cross-linked HA.
• Sterile packaging.
• Instructions for use and product information leaflet.

Storage Conditions

Proper storage of Monovisc® injections is crucial to ensure their effectiveness:

• Temperature: At a room temperature below 25°C.
• Avoid freezing: Do not freeze the product as it can damage the integrity of the HA.
• Protect from light: Keep in the original packaging to prevent exposure to light, which could degrade the product.
• Single-use only: Do not re-sterilise or reuse any components.

Who Can Administer This Orthopedic Injectable?

Monovisc® injections should only be administered by certified healthcare professionals, such as:

• Orthopaedic surgeons: Specialists in joint health and surgery.
• Rheumatologists: Experts in treating musculoskeletal diseases and arthritis.
• Trained personnel: Physicians or nurse practitioners with expertise in injections.

Mode of Administration

Administering Monovisc® requires adherence to specific protocols to ensure patient safety and treatment efficacy:

Pre-procedure:

• Patient evaluation: Confirm osteoarthritis diagnosis and rule out contraindications.
• Informed consent: Explain the procedure, benefits, and risks to the patient.
• Sterilisation: Clean the injection site thoroughly with an antiseptic solution.
• Local anaesthesia: Consider using local anaesthetic to reduce discomfort.

 

During procedure:

• Aspiration: If necessary, remove any excess fluid from the joint using a sterile syringe.
• Injection: Insert the sterile needle into the space and slowly inject Monovisc®.
• Imaging guidance: Use ultrasound or fluoroscopy to ensure accurate needle placement, especially in challenging cases.

 

Post-procedure:

• Compression: Apply a light compression bandage to reduce swelling.
• Observation: Monitor the patient for any immediate adverse reaction(s).
• Activity restrictions: Advise the patient to avoid strenuous activities for 48 hours.

Post-Treatment Care

Proper post-treatment care is essential to maximise the benefits of Monovisc® injections and patients should adhere to the following:

• Rest the joint: Avoid strenuous activities and excessive walking for at least 48 hours.
• Apply ice: Use ice packs to reduce swelling and discomfort.
• Elevate the leg: Keep the affected leg elevated to minimise swelling.
• Avoid high-impact activities: Refrain from running, jumping, or heavy lifting for a week.
• Pain management: Use over-the-counter relievers like acetaminophen if needed.
• Follow-up: Schedule a follow-up appointment to assess treatment effectiveness and discuss any concerns.

How Long Do Effects Last?

Monovisc® injections can provide relief for up to 6 months.

Regular follow-up injections may help maintain long-term benefits and delay the need for surgical interventions.

Injection Side Effects

While Monovisc® is generally well-tolerated, some patients may experience side effects. These are usually mild and temporary.

Common side effects:

• Mild discomfort: Temporary discomfort around the injection site.
• Swelling: Mild swelling in the treated area.
• Warmth or redness: Temporary warmth or redness at the insertion site.
• Stiffness: Slight stiffness in the treated joints, usually resolving within a few days.

 

Rare side effects:

• Infection: Severe pains, fever, or increased swelling indicating possible infection.
• Allergic reaction: Symptoms such as itching, rash, or difficulty breathing.
• Nerve damage: Uncommon but serious, potentially causing numbness or tingling.
• Bleeding or bruising: Unusual bleeding or significant bruising at the insertion site.

What Do Client Reviews Say?

Practitioners appreciate its single-dose convenience, reducing the number of visits required for treatment. The product’s high molecular weight HA provides longer-lasting relief compared to other options, making it a preferred choice for many specialists.

Patients report significant improvement in discomfort and mobility, often noticing relief within a few weeks of the treatment. Many patients express satisfaction with the reduced need for oral medications and the ability to delay or avoid surgery.

Contraindications for the Treatment

Monovisc® injections are not suitable for everyone. It is crucial to identify contraindications before proceeding with treatment.

• Allergy to HA products: Patients with known hypersensitivity to HA.
• Infection in the joint: Active infection or skin disease in the treatment area.
• Pregnancy and breastfeeding: Not recommended due to lack of safety data.
• Severe inflammation: Patients with acute inflammation should avoid this treatment.
• Bleeding disorders: Patients with bleeding disorders or taking anticoagulants should not receive Monovisc®.
• Underaged patients: Monovisc® was not clinically tested on patients under 21.

Who Can Buy Monovisc® Injections and Where?

Only certified medical professionals such as orthopaedic specialists, rheumatologists, pain management clinics, and specialised facilities can order Monovisc® injections online.

Purchasing Monovisc® from Nu Derma Supply, a verified and authorised vendor, ensures product authenticity, quality, and adherence to standards.

How Much Does an Injection Cost?

Monovisc® prices vary depending on the region and the supplier.

The Monovisc® pricing in the USA can range from $400 to $800 for a single dose, depending on the treatment facility and whether the cost is covered by insurance.

On the other hand, the pricing in the UK typically ranges between £200 and £400 per package. The exact cost will depend on the treatment area, practice fees, and whether additional services are included.

Medical professionals often purchase Monovisc® in bulk at wholesale pricing to reduce costs.

How Much Does a Hyaluronic Acid Injection Cost in the UK?

The cost of HA injections in the UK can vary widely based on the specific product and treatment facility.

Monovisc®, as a specialised single-dose HA treatment, may be priced at the higher end of this range due to its unique formulation and longer-lasting effects.

Is This Product Worth It?

For patients seeking long-lasting relief from osteoarthritis, Monovisc® is an effective and convenient treatment option.

Its single-treatment format, coupled with up to six months of relief, makes it a valuable choice for many.

While the cost may be higher than other treatments, the reduced need for frequent injections and the potential to delay surgery can make it a cost-effective option in the long run.